THE SUSTAINABLE NUTRITION GROUP LTD 
By
March 2014, on sales of its generic anti-coagulant drug fondaparinux. Alchemia will receive A$1.82 million (US$1.68 million) following its contribution of A$0.54 million (US$0.50 million) towards yield and cost of goods improvement activities, as previously announced. Such contributions will apply until the quarter ending 31 December 2014, after which time Alchemia's obligations to make such payments will cease.
During the quarter, Dr Reddy's total market share by volume in the US decreased marginally from 33% to 32% compared to the previous quarter. Seasonal buying patterns and channel consolidation in the US, the latter due to a number of retailer-wholesaler merges, adversely affected fondaparinux sales volumes in the current quarter. In addition, the overall fondaparinux market continued to experience both volume and price pressures (Source: IMS data).
"The March quarter is traditionally a lower profit period for fondaparinux. In addition, US channel consolidation temporarily affected orders in FY 3Q 2014," said Alchemia's CEO, Thomas Liquard. "We are satisfied with Dr Reddy's continued competitive performance and look forward to the results of FY 4Q 2014."
Dr Reddy's continues to work to expand the sale of fondaparinux into additional markets and is finalising arrangements for the launch fondaparinux in Canada. Dr Reddy's have also filed generic applications for fondaparinux in two additional emerging markets.
Further analysis of fondaparinux sales is provided in a presentation which will be released to the ASX
to accompany this press release.
Alchemia is a drug discovery and development company marketing FDA approved fondaparinux, an injectible antithrombotic in the US, as well as other major markets via partner Dr. Reddy's Laboratories. The Company is also developing a late stage oncology product pipeline with multiple ongoing trials through its proprietary HyACT drug delivery platform, which targets anti-cancer drugs to solid tumours. Lead asset HA-Irinotecan is in a pivotal Phase III clinical trial for the treatment of metastatic colorectal cancer. HA-Irinotecan is also in two Phase II investigator-sponsored trials, one of which is in collaboration with Merck Serono combining HA-Irinotecan with Erbitux® (cetuximab). Alchemia is also exploring additional small molecule drug discovery targets via an internal discovery platform VAST, based on the Company's deep chemistry expertise. The VAST technology is being
developed in collaboration with leading academic institutions and is partnered with AstraZeneca AB.
Page 1 of 2
www.alchemia.com.au
Erbitux® is a trademark of Merck KGaA.
www.alchemia.com.au
Alchemia Limited
Thomas Liquard
Chief Executive Officer
Alchemia Limited
Tel: +61 7 3340 0200
Tel: +61 4 0959 6164
Investor Relations USA
Laura Forman
Blueprint Life Science Group
+1 415 375 3340 Ext. 103 lforman@bplifescience.com
+61 3 9620 3333 emmap@monsoon.com.au
Page 2 of 2
www.alchemia.com.au
|
distributed by
|
